Partner News | Published: Monday, March 30, 2026
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is pleased to announce that GE HealthCare, a global healthcare solutions provider focused on advanced medical technology, and digital solutions that support clinicians in diagnosing and managing complex diseases, will expand education around the development of cardiac positron emission tomography (PET) programs.
Through its innovations in cardiovascular imaging and pharmaceutical diagnostics, GE HealthCare helps clinicians improve diagnostic confidence and clinical decision-making. Its most recent innovation, (flurpiridaz F 18 injection), aims to expand access to advanced cardiac imaging, including cardiac PET.
“We are always striving to work with organizations who can offer insights and innovative solutions to the MedAxiom community,” said Joe Sasson, PhD, executive vice president of ventures and chief commercial officer at MedAxiom. “GE HealthCare Pharmaceutical Diagnostics’ expertise in advanced cardiovascular imaging will bring valuable knowledge and perspectives to our members as they continue to develop new strategies and expand the use of advanced imaging in improving clinical decision-making.”
“Advancing cardiovascular care depends on strong collaboration across the cardiology community. Our work with MedAxiom reflects a shared commitment to education, clinical excellence and helping practices adopt the next generation of cardiovascular diagnostics,” said Natasha Phillips, chief marketing officer in the U.S. and Canada for the Pharmaceutical Diagnostics division of GE HealthCare. “Together we are working to expand access to advanced imaging so clinicians can detect disease earlier and make more informed treatment decisions.”
GE HealthCare has served patients and healthcare providers for more than 130 years and has been a valuable collaborator with the MedAxiom community. This expanded relationship will allow MedAxiom members to further leverage their expertise and solutions around improving diagnostic confidence and clinical decision-making, expanding access to advanced cardiac PET imaging, supporting operational efficiency and scalable care delivery.
About MedAxiom
MedAxiom, an ACC Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and coders, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
